3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for locally advanced or metastatic urothelial carcinoma with FGFR (fibroblast growth factor receptor) 3 gene mutations, as of Sunday.

The recent reimbursement listing is the result of applying a flexible incremental cost effectiveness ratio threshold. The clinical value of Balversa, the severity of the disease, and the innovativeness of the drug were positively considered during the evaluation process by the HIRA's Drug Reimbursement Review Committee and the negotiations with the National Health Insurance Service (NHIS).

Read Korea Biomedical Review article